SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer

British Journal of Cancer

Volumn 94, Issue 1, 2006, Pages 62-68

  Vasey, P A ^a,i   Atkinson, R ^b   Osborne, R ^c   Parkin, D ^d   Symonds, R ^e   Paul, J ^a   Lewsley, L ^a   Coleman, R ^f   Reed, N S ^a   Kaye, S ^g   Rustin, G J S ^h  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^c POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

^f WESTON PARK HOSPITAL   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h MOUNT VERNON HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carboplatin; Docetaxel; Gemcitabine; Ovarian cancer; Sequential therapy; Triple agent therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; DEXAMETHASONE; DOCETAXEL; DOMPERIDONE; GEMCITABINE; GRANISETRON;

ADULT; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DYSPNEA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LUNG TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN TOXICITY; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DYSPNEA; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 30644459425     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602909     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts & Figures 2004 (2004). Atlanta, GA: American Cancer Society
2. Barlow C, Nystrom M, Oesterling C, Fennell D, Ismay J, Gallagher C (2004) Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer. Br J Cancer 90: 1318-1322
3. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 57: 289-300
4. Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA (2003) Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin. Gynecol Oncol 89: 486-493
5. Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21(Suppl): 149s-167s
6. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
7. Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 41: 161-166
8. Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F (2001) A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes. Int J Cancer 92: 738-747
9. 51Cr-EDTA. Clin Sci 37: 169-180
10. Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, Chauvenet L, Gould A, on behalf of the EORTC Quality of Life Group (European Organization for Research and Treatment of Cancer) and the Scottish Gynaecological Cancer Trials Group (2001) Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37: 47-53
11. Gligorov J, Lotz J-P (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2): 3-8
12. Guastalla III JP, Dieras V (2003) The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 89(Suppl 3): S16-S22
13. Guppy AE, Nelstrop AE, Foster T, Agarwal R, Seckl MJ, Rustin GJ (2004) A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer. Br J Cancer 90: 810-814
14. Hansen SW (2002) Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma. Semin Oncol 29(1 Suppl 1): 17-19
15. Harries M, Moss C, Perren T, Gore M, Hall G, Everard M, A'Hern R, Gibbens I, Jenkins A, Shah R, Cole C, Pizzada O, Kaye S (2004) A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 91: 627-632
16. Hsu Y, Sood AK, Sorosky JI (2004) Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case - control analysis of toxicity. Am J Clin Oncol 27: 14-18
17. International Collaborative Ovarian Neoplasm (ICON) Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515
18. Jayson GC, Maenpaa J, Wilkinson PM, Ledermann JA, Welch RS, Cruickshank D, Chan S, Hindley A, Vasey PA, Fernebro E (2003) Randomized feasibility study of carboplatin followed by docetaxel or docetaxel/irinotecan in ovarian cancer (SCOTROC IIB). Proc Am Soc Clin Oncol 22: 449 (Abstract)
19. Kaye SB (2000) Intravenous chemotherapy for ovarian cancer - the state of the art? Int J Gynecol Cancer 10: 19-25
20. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936-3945
21. Mäenpää JU (2003) Docetaxel: promising and novel combinations in ovarian cancer. Br J Cancer 89(Suppl 3): S29-S34
22. Muggia FM (2003) Sequential single agents as first line chemotherapy for ovarian cancer: a strategy derived from the results of GOG132. Int J Gyn Cancer 13(Suppl 2): 156-162
23. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 18: 106-115
24. Poole CJ, Perren T, Burton A, Jordan SD, Jenkins AH, Mould JJ, Spooner DA, Luesley D, Chan KK, Sturman S, Earl HM (2000) Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer. Ann Oncol 11: 1603-1608
25. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997
26. Rustin GJS, Nelstrop AE, Tuxen MK, Lambert HE (1996) Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7: 361-364
27. Thomas AL, Cox G, Sharma RA, Steward WP, Shields F, Jeyapalan K, Muller S, O'Byrne KJ (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 36: 2329-2334
28. Tognoni A, Pronzato P, Cadenotti L, Ghio E, Manna N, Pensa F, Marino L (2000) Sequential high dose-density chemotherapy in advanced ovarian cancer. Anticancer Res 20: 3957-3961
29. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, the Scottish Gynaecological Cancer Trials Group (2004) Phase III randomized trial of docetaxel - carboplatin versus paclitaxel - carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691